CTLA4 and lymphoma: It can be foreseen that efficacy of actual checkpoint inhibition, targeting PD-1/PD-L1 (and CTLA-4), could be ameliorated when we contemplate and consider using some of the myriad of checkpoint molecules involved in the interactions of immune cells capable of killing lymphoma cells [80].